Positions

Overview

  • Dr. Overton joined the UAB faculty in 2011 to assist in the development of the translational research program in the field of vaccinology and to establish a comprehensive hepatitis C program. He serves as the Co-Director of the AVRC and the Clinic Director for the 1917 Hepatitis Clinic. He is Board-certified in Medicine and Infectious Diseases and is licensed to practice in Alabama. His research interests focus on the chronic inflammation and long-term complications of chronic viral infections, specifically HIV and viral hepatitis, as well as understanding the underlying immune system with regards to vaccines and HIV infection. He has published numerous papers on many aspects of the complications of HIV infection. Specifically, he has evaluated vaccine responses among HIV-infected persons in an effort to better characterize the impact of this immunosuppressive state on the development of both humoral and cellular immune responses. He has conducted studies of hepatitis A, hepatitis B, HPV, HIV, anthrax, smallpox, zoster, and influenza vaccines.

    Dr. Overton’s clinical duties include seeing HIV-infected and chronic hepatitis patients in the outpatient setting as well as seeing solid organ and bone marrow transplant patients in the hospital. He has developed strong relationships with the UAB hepatology group as well as the bone marrow transplant unit and can readily identify potential study participants from these high risk populations. In addition, he has considerable experience in performing clinical trials, both randomized controlled trials and observational studies, assessing various parameters related to HIV, HCV, and vaccine responses. He has also served as the lead investigator on several trials within the AIDS Clinical Trial Group.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Association Between Metformin Use and Cognitive and Physical Function in Persons with HIV and Diabetes.AIDS Research and Human Retroviruses2023
    2022 Brief Report: Intracellular Cystatin B Levels Are Altered in HIV-Infected Participants With Respect to Neurocognitive Status and Antiretroviral Therapy 2022
    2022 Optimization of methods for the accurate characterization of whole blood neutrophilsScientific Reports.  12. 2022
    2022 Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease riskAIDS.  36:1997-2003. 2022
    2022 Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic SubstudyJournal of Infectious Diseases.  226:1809-1822. 2022
    2022 Chlamydia Vaccination: Parent Opinions and Implications for Future Promotion ProgramsSexually Transmitted Diseases.  49:745-749. 2022
    2022 Perceived Need and Acceptance of a Future Chlamydia Vaccine among Health Care ProvidersSexually Transmitted Diseases.  49:740-744. 2022
    2022 Trends in diabetes incidence and associated risk factors among people with HIV in the current treatment eraAIDS.  36:1811-1818. 2022
    2022 Bacterial Sexually Transmitted Infection Incidence Among Southern Men Who Have Sex With Men With Human Immunodeficiency Virus in the Treatment as Prevention Era, 2014-2019Clinical Infectious Diseases.  75:1446-1448. 2022
    2022 Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral TherapyClinical Infectious Diseases.  75:1324-1333. 2022
    2022 Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus and Associations With Cardiometabolic RiskClinical Infectious Diseases.  75:1154-1163. 2022
    2022 Obesity in HIV infection: Host-pathogen interactionAIDS.  36:1477-1491. 2022
    2022 Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIVAIDS Research and Human Retroviruses.  38:735-742. 2022
    2022 Asymptomatic SARS-CoV-2 Infection Is Common among ART-Treated People with HIV 2022
    2022 COVID-19 Vaccination Rates in a Global HIV CohortJournal of Infectious Diseases.  225:603-607. 2022
    2022 Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsAIDS.  36:205-214. 2022
    2022 Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency VirusClinical Infectious Diseases.  74:95-104. 2022
    2021 A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People with HIV on Antiretroviral TherapyOpen Forum Infectious Diseases.  8. 2021
    2021 Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People with Human Immunodeficiency VirusOpen Forum Infectious Diseases.  8. 2021
    2021 Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE TrialClinical Infectious Diseases.  73:2009-2022. 2021
    2021 Incident bone fracture and mortality in a large HIV cohort outpatient study, 2000–2017, USAArchives of Osteoporosis.  16. 2021
    2021 Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 StudyJournal of Clinical Pharmacology.  61:1555-1566. 2021
    2021 Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyLancet HIV.  8:e679-e689. 2021
    2021 Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) 2021
    2021 Suspected Immune-Related Adverse Events with an Anti-PD-1 Inhibitor in Otherwise Healthy People with HIV 2021
    2021 Cabotegravir for HIV prevention in cisgender men and transgender womenNew England Journal of Medicine.  385:595-608. 2021
    2021 Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary studyMedicine.  100:E26588. 2021
    2021 Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis PopulationKidney International Reports.  6:1788-1798. 2021
    2021 Recurrent COVID-19 in Hemodialysis: A Case Report of 2 Possible ReinfectionsKidney Medicine.  3:447-450. 2021
    2021 Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipientsAmerican Journal of Transplantation.  21:938-949. 2021
    2021 Erratum: Patterns of antiretroviral therapy use and immunologic profiles at enrollment in the REPRIEVE trial (The Journal of Infectious Diseases (2020) 222:S1 (S8-S19) DOI: 10.1093/infdis/jiaa259)Journal of Infectious Diseases.  223:352. 2021
    2021 Assessment of Coronary Artery Disease with Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers among Adults with HIV Eligible for Primary Cardiovascular PreventionJAMA Network Open2021
    2021 One-year statin persistence and adherence in adults with HIV in the United StatesJournal of Clinical Lipidology.  15:181-191. 2021
    2020 Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study 2020
    2020 Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials 2020
    2020 Hepatitis C among high-risk alabamians: Disease burden and screening effectivenessJournal of Infectious Diseases.  222:S365-S375. 2020
    2020 An evaluation of baseline kidney function in the REPRIEVE trial of pitavastatin in human immunodeficiency virusJournal of Infectious Diseases.  222:S41-S51. 2020
    2020 Patterns of antiretroviral therapy use and immunologic profiles at enrollment in the REPRIEVE trialJournal of Infectious Diseases.  222:S8-S19. 2020
    2020 Physical function impairment and frailty in middle-aged people living with human immunodeficiency virus in the REPRIEVE trial ancillary study PREPAREJournal of Infectious Diseases.  222:S52-S62. 2020
    2020 Immune Activation and Inflammation in People with Human Immunodeficiency Virus: Challenging TargetsJournal of Infectious Diseases.  221:1567-1570. 2020
    2020 Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infectionNew England Journal of Medicine.  382:1124-1135. 2020
    2020 A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDSVaccine.  38:2600-2607. 2020
    2020 Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008–2015Progress in Cardiovascular Diseases.  63:170-177. 2020
    2020 Sexually transmitted infections and sexual behaviors of men who have sex with men in an American Deep South PrEP clinicInternational Journal of STD and AIDS.  31:127-135. 2020
    2020 Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination 2020
    2020 Direct acting antivirals in hepatitis c-infected kidney transplant recipients: Associations with long-term graft failure and patient mortalityPathogens and Immunity.  5:275-290. 2020
    2020 Obesity Affects the Association of Bioelectrical Impedance Phase Angle With Mortality in People Living With HIVJournal of the Association of Nurses in AIDS Care.  31:51-59. 2020
    2019 Brief Report: Aging Attenuates the Association between Coronary Artery Calcification and Bone Loss among HIV-Infected Persons 2019
    2019 Cognitive Reserve over the Lifespan: Neurocognitive Implications for Aging with HIVJournal of the Association of Nurses in AIDS Care.  30:E109-E121. 2019
    2019 Rapid boosting of HIV-1 neutralizing antibody responses in humans following a prolonged immunologic rest periodJournal of Infectious Diseases.  219:1755-1765. 2019
    2019 Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersAmerican Heart Journal.  212:1-12. 2019
    2019 Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)American Heart Journal.  212:23-35. 2019
    2019 Associations of food insecurity and psychosocial measures with diet quality in adults aging with HIV 2019
    2019 Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 2019
    2019 Vitamin D does not modulate immune-mediated bone loss during ART initiationAntiviral Therapy.  24:355-362. 2019
    2018 HIV-1 latent reservoir size and diversity are stable following brief treatment interruptionJournal of Clinical Investigation.  128:3102-3115. 2018
    2018 Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virusJournal of Clinical Lipidology.  12:988-998.e5. 2018
    2018 Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune statusAIDS.  32:1279-1287. 2018
    2018 Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status.AIDS.  32:1279-1287. 2018
    2018 The hidden risk: Incorporating inflammation and HIV serostatus into coronary artery disease screeningJournal of Nuclear Cardiology.  25:884-886. 2018
    2018 Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trialPLoS One.  13. 2018
    2018 Reply 2018
    2018 Reply. 2018
    2017 The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with Human Immunodeficiency Virus InfectionClinical Infectious Diseases.  65:2042-2049. 2017
    2017 Genome-wide admixture and association study of subclinical atherosclerosis in the Women’s Interagency HIV Study (WIHS)PLoS One.  12. 2017
    2017 Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected WomenClinical Infectious Diseases.  65:1695-1702. 2017
    2017 Racial differences in calculated bioavailable Vitamin D with Vitamin D/calcium supplementationAIDS.  31:2337-2344. 2017
    2017 Direct-acting antivirals in kidney transplant patients: Successful hepatitis c treatment and short-term reduction in urinary protein/creatinine ratiosPathogens and Immunity.  2:366-375. 2017
    2017 Examining Sexual Function among Individuals with HIV in a Midwestern US Urban Outpatient Clinic SettingJournal of the International Association of Providers of AIDS Care.  16:481-486. 2017
    2017 The Relationship of Social Support and Neighborhood Perceptions among Individuals with HIVJournal of the International Association of Providers of AIDS Care.  16:440-445. 2017
    2017 Monocyte bioenergetic function is associated with body composition in virologically suppressed HIV-infected womenRedox Biology.  12:648-656. 2017
    2017 Race and sex differences in ambulatory blood pressure measures among HIV+ adultsJournal of the American Society of Hypertension.  11:420-427.e3. 2017
    2017 Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected personsPLoS One.  12. 2017
    2017 Admixture Mapping of Subclinical Atherosclerosis and Subsequent Clinical Events among African Americans in 2 Large Cohort StudiesCirculation: Cardiovascular Genetics.  10. 2017
    2017 Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access among African American Men, Women, and MSM in the Deep South 2017
    2017 Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 InfectionPLoS Pathogens.  13. 2017
    2017 Local ancestry and clinical cardiovascular events among African Americans from the atherosclerosis risk in communities studyJournal of the American Heart Association.  6. 2017
    2017 Vitamin D Supplementation Does Not Affect Metabolic Changes Seen with ART InitiationOpen Forum Infectious Diseases.  4. 2017
    2016 Duration of Influenza Virus Shedding among HIV-Infected Adults in the cART Era, 2010-2011AIDS Research and Human Retroviruses.  32:1180-1186. 2016
    2016 Effect of HIV antibody VRC01 on viral rebound after treatment interruptionNew England Journal of Medicine.  375:2037-2050. 2016
    2016 Characterizing failure to establish hepatitis C care of baby boomers diagnosed in the emergency departmentOpen Forum Infectious Diseases.  3. 2016
    2016 Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the EvidenceCurrent HIV/AIDS Reports.  13:289-296. 2016
    2016 Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/Hepatitis C virus-coinfected patientsAIDS Research and Human Retroviruses.  32:325-328. 2016
    2016 Psychiatric Diagnoses among an HIV-Infected Outpatient Clinic PopulationJournal of the International Association of Providers of AIDS Care.  15:126-130. 2016
    2016 Ambulatory blood pressure monitoring in individuals with HIV: A systematic review and meta-analysisPLoS One.  11. 2016
    2016 Incidence and predictors of abnormal anal cytology findings among HIV-infected adults receiving contemporary antiretroviral therapyJournal of Infectious Diseases.  213:351-360. 2016
    2016 Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: Results of an exploratory substudy of METABOLIK, a phase 4, randomized trialHIV Clinical Trials.  17:72-77. 2016
    2016 High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years among HIV-Infected Persons in the Era of Modern Antiretroviral TherapyAIDS Research and Human Retroviruses.  32:59-67. 2016
    2016 Low bone mineral density and risk of incident fracture in HIV-infected adultsAntiviral Therapy.  21:45-54. 2016
    2016 The Silent Epidemic - Frailty and Aging with HIV. 2016
    2016 Vitamin D and bone loss in HIVCurrent Opinion in HIV and AIDS.  11:277-284. 2016
    2015 Mechanisms Influencing Circadian Blood Pressure Patterns Among Individuals with HIVCurrent Hypertension Reports.  17. 2015
    2015 Normal T-cell activation in elite controllers with preserved CD4 + T-cell countsAIDS.  29:2245-2254. 2015
    2015 Extended-release niacin versus fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: Effects on endothelial function, lipoproteins, and inflammationClinical Infectious Diseases.  61:840-849. 2015
    2015 Obesity is Associated with Race/Sex Disparities in Diabetes and Hypertension Prevalence, but Not Cardiovascular Disease, among HIV-Infected AdultsAIDS Research and Human Retroviruses.  31:898-904. 2015
    2015 Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1New England Journal of Medicine.  373:714-725. 2015
    2015 Maternal post-absorptive leucine kinetics during late pregnancy in US women with HIV taking antiretroviral therapy: A cross-sectional pilot studyClinical nutrition ESPEN.  10:e140-e146. 2015
    2015 Vitamin D and Calcium attenuate bone loss with antiretroviral therapy initiation: A Randomized TrialACP journal club.  162:815-824. 2015
    2015 Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: An open-label, controlled clinical phase II trialOpen Forum Infectious Diseases.  2. 2015
    2015 Impact of poor retention in HIV medical care on hepatitis B vaccinationJournal of the International Association of Providers of AIDS Care.  14:185-190. 2015
    2015 Persistent HIV-related stigma among an outpatient US clinic population.International Journal of STD and AIDS.  26:243-250. 2015
    2015 Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency departmentHepatology.  61:776-782. 2015
    2015 Preliminary outcomes of a pilot physical therapy program for HIV-infected patients with chronic pain 2015
    2015 A better screening tool for HIV-associated neurocognitive disorders: Is it what clinicians need?AIDS.  29:895-902. 2015
    2015 Inhibition of the lymphocyte metabolic switch by the oxidative burst of human neutrophilsClinical Science.  129:489-504. 2015
    2015 Parks as a tool for HIV managementJournal of the International Association of Providers of AIDS Care.  14:8-11. 2015
    2014 Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary careClinical Infectious Diseases.  59:1686-1693. 2014
    2014 National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United StatesClinical Infectious Diseases.  59:755-764. 2014
    2014 Improving cervical cancer screening rates in an urban HIV clinic 2014
    2014 Bone alterations associated with HIVCurrent HIV/AIDS Reports.  11:233-240. 2014
    2014 Depression severity is associated with increased risk behaviors and decreased CD4 cell counts 2014
    2014 Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia ankara vaccines expressing HIV-1 virus-like particlesJournal of Infectious Diseases.  210:99-110. 2014
    2014 Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort 2014
    2014 Beliefs, experience, and interest in pharmacotherapy among smokers with HIVAmerican Journal of Health Behavior.  38:284-296. 2014
    2014 Metabolic consequences of HIV: Pathogenic insightsCurrent HIV/AIDS Reports.  11:35-44. 2014
    2014 Bones, fractures, antiretroviral therapy and HIV topical collection on HIV/AIDSCurrent Infectious Disease Reports.  16. 2014
    2014 Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patientsAIDS.  28:2627-2631. 2014
    2014 Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected Adults. 2014
    2014 HIV-Related Metabolic Comorbidities in the Current ART EraInfectious Disease Clinics of North America.  28:457-476. 2014
    2014 Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humansVaccine.  32:5490-5495. 2014
    2014 Metabolic complications of HIV infection and its therapiesTopics in antiviral medicine.  22:651-654. 2014
    2013 Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scaleJournal of Neuroimmune Pharmacology.  8:1114-1122. 2013
    2013 Are neighborhood conditions associated with HIV management?HIV Medicine.  14:624-632. 2013
    2013 Relationships among HIV infection, metabolic risk factors, and left ventricular structure and functionAIDS Research and Human Retroviruses.  29:1151-1160. 2013
    2013 Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental deathClinical Infectious Diseases.  56:1471-1479. 2013
    2013 Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviraltreated HIV-infected adults in the USAntiviral Therapy.  18:65-75. 2013
    2013 Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical careJournal of the International Association of Providers of AIDS Care.  12:138-141. 2013
    2013 Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia ankara as a smallpox vaccine in HIV-infected subjectsJournal of Infectious Diseases.  207:749-758. 2013
    2013 The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected personsJournal of NeuroVirology.  19:109-116. 2013
    2013 Pain is independently associated with impaired physical function in HIV-infected patientsPain Medicine.  14:1985-1993. 2013
    2013 Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in hiv-positive individuals with metabolic complicationsHIV Clinical Trials.  14:303-312. 2013
    2012 Screening anxiety in the HIV clinicAIDS and Behavior.  16:2407-2413. 2012
    2012 Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in uteroAIDS.  26:2053-2058. 2012
    2012 Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeksAIDS Research and Human Retroviruses.  28:1184-1195. 2012
    2012 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factorsJournal of inflammation.  9. 2012
    2012 Urban farming: A non-traditional intervention for HIV-related distressAIDS and Behavior.  16:1238-1242. 2012
    2012 Sometimes, more is betterJournal of Infectious Diseases.  205:697-699. 2012
    2012 Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapyAIDS Research and Human Retroviruses.  28:259-264. 2012
    2012 Cystatin C and baseline renal function among HIV-infected persons in the SUN studyAIDS Research and Human Retroviruses.  28:148-155. 2012
    2012 Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the united statesSexually Transmitted Diseases.  39:154-160. 2012
    2012 Reply to Ganesan et alJournal of Infectious Diseases.  205:518-519. 2012
    2012 Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veteransAIDS.  26:229-234. 2012
    2012 A Review of Opioid Prescribing Practices and Associations with Repeat Opioid Prescriptions in a Contemporary Outpatient HIV ClinicPain Practice.  12:440-448. 2012
    2012 Effect of darunavir on lipid profile in HIV-infected patientsHIV Clinical Trials.  13:256-270. 2012
    2012 Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: Implications for prevention interventionsSexually Transmitted Diseases.  39:1-7. 2012
    2012 Serostatus disclosure among adults with HIV in the era of HIV therapy 2012
    2011 Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysisCardiovascular Diabetology.  10. 2011
    2011 Performances on the cogstate and standard neuropsychological batteries among HIV patients without dementiaAIDS and Behavior.  15:1902-1909. 2011
    2011 Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohortClinical Infectious Diseases.  53:826-835. 2011
    2011 A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated agingCurrent Aging Science.  4:33-41. 2011
    2011 Increasing clarity on bone loss associated with antiretroviral initiationJournal of Infectious Diseases.  203:1705-1707. 2011
    2011 Erratum: High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy (Clinical Infectious Diseases (2011) 52 (378-386))Clinical Infectious Diseases.  52:1200. 2011
    2011 Factors associated with non-adherence to antiretroviral therapy in the SUN study 2011
    2011 Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individualsVaccine.  29:3558-3563. 2011
    2011 Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (The SUN Study)Sexually Transmitted Diseases.  38:253-259. 2011
    2011 High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapyClinical Infectious Diseases.  52:378-386. 2011
    2011 Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general populationClinical Infectious Diseases.  52:396-405. 2011
    2011 The rapidly evolving research on vitamin D among HIV-infected populationsCurrent Infectious Disease Reports.  13:83-93. 2011
    2011 Alcohol consumption is associated with poor health in HIV clinic patient population: A behavioral surveillance studyAIDS and Behavior.  15:209-213. 2011
    2011 Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity 2011
    2011 GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals.Open Virology Journal.  5:109-113. 2011
    2011 Perceptions of alcohol risk among individuals living with HIV 2011
    2011 STD/HIV risk among adults in the primary care setting: Are we adequately addressing our patients'needs?Sexually Transmitted Diseases.  38:30-32. 2011
    2010 Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United StatesJournal of Infectious Diseases.  202:1567-1576. 2010
    2010 Bone disease in HIV infection: A practical review and recommendations for HIV care providersClinical Infectious Diseases.  51:937-946. 2010
    2010 Do brief screening questions or provider perception accurately identify persons with low health literacy in the HIV primary care setting? 2010
    2010 Differences and changes in human papillomavirus type 16 variant status in human immunodeficiency virus-positive adults are not uncommonJournal of General Virology.  91:2068-2072. 2010
    2010 Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220Vaccine.  28:5597-5604. 2010
    2010 Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factorsHIV Medicine.  11:379-388. 2010
    2010 Comparisons of sexual behaviors and STD prevalence among older and younger individuals with HIV infection 2010
    2010 The interplay of sociodemographic factors on virologic suppression among a U.S. outpatient HIV clinic population 2010
    2010 Sexual behaviors and results of bacterial sexually transmitted infections testing among frail HIV-infected individualsJournal of the International Association of Providers of AIDS Care.  9:30-33. 2010
    2010 Aging and HIV infection: A comparison between older HIV-infected persons and the general populationHIV Clinical Trials.  11:100-109. 2010
    2010 Renal and Urologic Emergencies in the HIV-infected PatientEmergency Medicine Clinics of North America.  28:343-354. 2010
    2010 The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.Journal of Clinical Pharmacology.  50:1050-1055. 2010
    2009 A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIVExpert Opinion on Drug Safety.  8:683-694. 2009
    2009 Frailty among HIV-infected persons in an urban outpatient care settingJournal of Infection.  59:346-352. 2009
    2009 Routine screening for depression: Identifying a challenge for successful HIV care 2009
    2009 Can you hear me now? Limited use of technology among an urban HIV-infected cohort 2009
    2009 Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcomeHIV Medicine.  10:439-446. 2009
    2009 Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapyHIV Medicine.  10:343-350. 2009
    2009 The study to understand the natural history of HIV and AIDS in the Era of effective therapy (SUN study)American Journal of Epidemiology.  169:642-652. 2009
    2009 HIV and aging: two converging epidemics.Missouri medicine.  106:269-273. 2009
    2008 Adverse effects of tenofovir use in HIV-infected pregnant women and their infantsAnnals of Pharmacotherapy.  42:1581-1585. 2008
    2008 Effect of postpartum HIV treatment discontinuation on long-term maternal outcomeJournal of the International Association of Providers of AIDS Care.  7:245-251. 2008
    2008 Incidence of sexually transmitted infections among HIV-infected women using depot medroxyprogesterone acetate contraceptionContraception.  78:125-130. 2008
    2008 The aging of the HIV epidemicCurrent HIV/AIDS Reports.  5:150-158. 2008
    2008 Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals 2008
    2007 An overview of vaccinations in HIVCurrent HIV/AIDS Reports.  4:105-113. 2007
    2007 Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women 2007
    2007 FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infectionBlood.  109:3786-3793. 2007
    2007 Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV+ individualsHIV Clinical Trials.  8:173-181. 2007
    2007 Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient populationClinical Infectious Diseases.  44:726-734. 2007
    2007 Predictors of immunity after hepatitis a vaccination in HIV-infected personsJournal of Viral Hepatitis.  14:189-193. 2007
    2007 Factors associated with seronegative chronic hepatitis C virus infection in HIV infectionClinical Infectious Diseases.  44:577-583. 2007
    2006 Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinicAIDS.  20:2115-2116. 2006
    2006 Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapyHIV Medicine.  7:437-441. 2006
    2005 Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosisClinical Infectious Diseases.  41:1326-1332. 2005
    2005 Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected personsClinical Infectious Diseases.  41:1045-1048. 2005
    2005 Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancyAIDS.  19:1439. 2005

    Chapter

    Year Title Altmetric
    2013 Infections of the immunocompromised patient.  704-709. 2013
    2012 Infections of the immunocompromised patient.  704-709. 2012
    2012 Prevention of hepatitis infection in HIV-Infected patients.  151-161. 2012

    Principal Investigator On

  • A-Z Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"  awarded by SOCIAL & SCIENTIFIC SYSTEMS
  • A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"  awarded by Brigham and Women's Hospital
  • A5361s: Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)  awarded by University of California, Los Angeles
  • A5361s: Pitvastatin to Reduce Physical Function Impairment and Frailty in HIV  awarded by Brigham and Women's Hospital
  • A5391- Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)  awarded by University of California, Los Angeles
  • ACTG Protocol Funds  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group (ACTG) A5332/A5340 Salary Support  awarded by Brigham and Women's Hospital
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: PF Chair A5332]  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: TSG-Sci Comm] Sub award# 1560 G YB529  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group: Protocol Funds  awarded by Brigham and Women's Hospital
  • AIDS Clinical Trials Group: Protocol Funds FTE Funding  awarded by Brigham and Women's Hospital
  • Aids Clinical Trials Group (ACTG) - TSG/Research Science Committee  awarded by Brigham and Women's Hospital
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Ancillary Studies of NAFLD and NASH in HIV infected Adults  awarded by Indiana University
  • Ancillary Studies of NAFLD and NASH in HIV infected Adults - Fixed Price  awarded by Indiana University
  • Ancillary Studies of NAFLD and NASH in HIV infected Adults - Zydus Clinical Trial Aim 4  awarded by Indiana University
  • Cardiovascular Disease Risk in HIV-Infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction Among REPRIEVE Trial Participants  awarded by Brigham and Women's Hospital
  • Effect of Low Dose Methotrexate on Endothelial Function and Inflammation in HIV - A5314  awarded by Brigham and Women's Hospital
  • Effect of Pitavastatin on Kidney Function in HIV-infected Persons  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Evaluating Nonavalent HPV Vaccine Immunogenicity among Adult Renal Transplant Recipients (Fixed Price Agreement)  awarded by Northwestern University
  • Evaluating Nonavalent HPV vaccine Immunogenicity among Adult Renal Transplant Recipients  awarded by Northwestern University
  • HPTN 083 A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender  awarded by FAMILY HEALTH INTERNATIONAL
  • HPTN 083-A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men (ViiV)  awarded by FAMILY HEALTH INTERNATIONAL
  • HPTN Personal Protective Equipment- HPTN Studies  awarded by FAMILY HEALTH INTERNATIONAL
  • HPTN Unanticipated Clinical Trials Costs  awarded by FAMILY HEALTH INTERNATIONAL
  • High VS. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients  awarded by VANDERBILT UNIVERSITY
  • Leadership And Operations Center (LOC), AIDS Clinical Trials Group (ACT6) [UM1AI068636]-A5332 Committee Chair Support  awarded by University of California, Los Angeles
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) (UM1A068636-13)  awarded by University of California, Los Angeles
  • Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)  awarded by University of Colorado
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Janssen
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by GlaxoSmithKline
  • Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)  awarded by MASSACHUSETTS GENERAL HOSPITAL
  • Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332) and ACTG A5333s The Mechanistic Substudy of REPRIEVE  awarded by MASSACHUSETTS GENERAL HOSPITAL
  • UAB Center for AIDS Research - The Detrimental Nexus of HCV and HIV Infection on Bioenergetics and Immune Function  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Investigator On

  • (CSSC-001) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. control( SARS-CoV-2 non-immune plasma) among Adults Exposed to COVID-19 and (CSSC-004) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune plasma)  awarded by Johns Hopkins University
  • Alabama - Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION
  • Amplifying Our Voice: Understanding HIV PrEP Promotional Messaging to Create Authentic PrEP Content by Men Who Have Sex with Men in the Deep South  awarded by National Institute of Mental Health/NIH/DHHS
  • COMPLETED - SPORE in Cervical Cancer - Project 3  awarded by Johns Hopkins University
  • Center For AIDS Research - Social Determinants of Health Disparities and Multiple Co-Morbidities among Men and Women Living with HIV  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Clincial Research Site Activities for the LTE to HVTN 117/HPX2004  awarded by Hutchinson (Fred) Cancer Research Center
  • CoVPN 3002 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • CoVPN 3003 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • CoVPN 3006 Protocol Funding (PF) - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • CoVPN 5001 (Acute Immune Responses to SARS-CoV-2 Infection) Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER ^
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplement to Stimulate Research in HIV/AIDS Cancer Research  awarded by National Cancer Institute/NIH/DHHS
  • Convalescent Plasma Randomized Clinical Trials for SARS-CoV-2 Prophylaxis and Early COVID-19 Treatment are Foundational for Subsequent Hyperimmune Globulin and Vaccines  awarded by Johns Hopkins University
  • Determining the Structural- and Functional-Level Effects of Diet-Specific Interventions on the Gut Microbiota of a Racially Diverse Sample of Southern United States Adults  awarded by National Cancer Institute/NIH/DHHS
  • Establishing Normative Cognitive Data for UAB Medical Professionals  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • HOPE in Action: A Clinical Trial of HIV-to-HIV Liver Transplantation  awarded by Johns Hopkins University
  • HPTN 078: Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States  awarded by FAMILY HEALTH INTERNATIONAL
  • HPX3002/HVTN 706 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding Year 14  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 405/HPTN 1901 Protocol Funding (PF) - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 505 Protocol Implementation Funds  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 703/HPTN 081 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 703/HPTN 081 Site Readiness  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 704/HPTN 085 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 704/HPTN 085 Protocol Funding (PF) - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (Pf): Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding Year 13  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding Year 16  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Implementation Funds  awarded by Hutchinson (Fred) Cancer Research Center
  • Hope in Action: A Clinical Trial of HIV-to-HIV Liver Transplantation  awarded by Johns Hopkins University
  • Impact of CCR5 Blockade in HIV+Kidney Transplant Recipients  awarded by University of California, San Francisco
  • Interdisciplinary Training In Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Interdisciplinary Training in Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Kidney Undergraduate Research Experience (KURE)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) COVID 19 SUPPLEMENT  awarded by Emory University
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 117/118  awarded by Hutchinson (Fred) Cancer Research Center
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 118/HPX2003 - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • Neutrophil Dysregulation as a Driving Mechanism of Cardiovascular Disease in HIV-1-Infection  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Population Genetics Analysis Program: Immunity to Vaccines/Infections II  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by HEMISPHERX BIOPHARMA, INC.
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by VICAL, INC.
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GENECURE BIOTECHNOLOGIES, LLC
  • Private Grant  awarded by CEPHEID
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by JANSSEN R&D IRELAND
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by VICAL, INC.
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by PROTEUS DIGITAL HEALTH, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Private Grant  awarded by SANOFI PASTEUR LIMITED
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Regional AIDS Education and Training Centers-Base  awarded by Emory University
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University
  • Screening, Evaluation, and Treatment of Anal Intraepithelial Neoplasia  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • The Guts of HIV: Innate Immune Dysregulation as a Central Mechanism of Gastrointestinal and Liver Disease in HIV-1-Infected Individuals  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research (CFAR)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research (CFAR)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Clinical Core C  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Core C - Clinical Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Lipidomic Profiling in HIV Patients Newly Initiating Antiretroviral Treatment  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - The Microbiome, Diet, and Incomplete CD4 Recovery on Antiretroviral Therapy  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - The Role of HIV-Infection and Antiretroviral Therapy Related Mitochondrial Toxicity in Accelerated Aging  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • UAB Institutional Career Development Program in HIV-Related Heart, Lung, Blood and Research  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • UAB-MISS WIHS Cohort  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Unsolicited R24 CFAR Network of Clinical Systems (CNICS)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • VVTEU Protocol Development and Implementation for Task Areas B-C Phase II Vaccine Trial for Influenza (“Flu Pandemic” or “H7”)  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER ^
  • Vaccine and Treatment Evaluation Units  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER ^
  • Vaccine and Treatment Evaluation Units - Admin Task  awarded by VANDERBILT UNIVERSITY
  • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • Barnes-Jewish West County Hospital, Postdoctoral Fellowship
  • Doctor of Medicine in Internal Medicine Residency Program, University of Tennessee System : Memphis 1999
  • Bachelor of Arts in English / Language Arts Teacher Education, University of Tennessee System : Knoxville 1992
  • Full Name

  • Edgar Overton